{
  "id": "61f602a3882a024a1000001f",
  "type": "yesno",
  "question": "Is Cabotegravir effective for HIV prevention?",
  "ideal_answer": "Yes, Cabotegravir is effective for HIV prevention.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27799824",
    "http://www.ncbi.nlm.nih.gov/pubmed/34482355",
    "http://www.ncbi.nlm.nih.gov/pubmed/34379922",
    "http://www.ncbi.nlm.nih.gov/pubmed/34029457",
    "http://www.ncbi.nlm.nih.gov/pubmed/32462541",
    "http://www.ncbi.nlm.nih.gov/pubmed/30012774",
    "http://www.ncbi.nlm.nih.gov/pubmed/30445896",
    "http://www.ncbi.nlm.nih.gov/pubmed/30811880",
    "http://www.ncbi.nlm.nih.gov/pubmed/26633643",
    "http://www.ncbi.nlm.nih.gov/pubmed/34871188",
    "http://www.ncbi.nlm.nih.gov/pubmed/29633869",
    "http://www.ncbi.nlm.nih.gov/pubmed/26049951",
    "http://www.ncbi.nlm.nih.gov/pubmed/33347943",
    "http://www.ncbi.nlm.nih.gov/pubmed/31644481",
    "http://www.ncbi.nlm.nih.gov/pubmed/33112699",
    "http://www.ncbi.nlm.nih.gov/pubmed/31447590",
    "http://www.ncbi.nlm.nih.gov/pubmed/33957367",
    "http://www.ncbi.nlm.nih.gov/pubmed/26049948",
    "http://www.ncbi.nlm.nih.gov/pubmed/29746267",
    "http://www.ncbi.nlm.nih.gov/pubmed/33740057",
    "http://www.ncbi.nlm.nih.gov/pubmed/32492704"
  ],
  "snippets": [
    {
      "text": "A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871188",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE OF REVIEW: Cabotegravir (CAB) and rilpivirine (RPV) is the first long-acting injectable antiretroviral therapy (ART) option approved for virologically suppressed adults with HIV-1. In addition, long-acting CAB is a promising agent for HIV preexposure prophylaxis (PrEP). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871188",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY: Clinical trial results support the use of long-acting CAB for HIV PrEP and long-acting CAB and RPV as a switch strategy for adults with HIV-1 who are first virologically suppressed with oral ART. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871188",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: We had previously shown that long-acting cabotegravir (CAB-LA) injections fully protected macaques from vaginal simian HIV (SHIV) infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482355",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492704",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Long-acting cabotegravir (CAB LA) is a potential new injectable formulation for human immunodeficiency virus (HIV) PrEP being tested in phase III trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Design and Testing of a Cabotegravir Implant for HIV Prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33347943",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31447590",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre-exposure prophylaxis of HIV-1 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30811880",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) infection, the integrase strand transfer inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32462541",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Long-acting injectable cabotegravir for the prevention of HIV infection",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31644481",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33740057",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Here, we review trials of cabotegravir (CAB) as treatment of HIV-1 infection and its potential use as pre-exposure prophylaxis (PrEP) in high risk individuals, including issues around oral lead in and potential resistance emergence. Exper",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29633869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "frequent dosing. This review focuses on the potential benefits and considerations for the study and use of 2 long-acting injectable agents, cabotegravir (GSK1265744LA, CAB LA) and rilpivirine (TMC278LA, RPV LA), for use as chemoprophylaxis for HIV ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633643",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An evaluation of cabotegravir for HIV treatment and prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33112699",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir long-acting for HIV-1 prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049951",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30012774",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799824",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34029457",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379922",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir is a novel human immunodeficiency virus integrase enzyme inhibitor used for prevention and treatment of HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33957367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26049948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29633869",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29746267",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445896",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}